Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Fate Therapeutics, Inc. (FATE : NSDQ)

• Company Description    Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate. Number of Employees: 181

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 2,231,139 shares Shares Outstanding: 115.33 (millions) Market Capitalization: $123.40 (millions) Beta: 2.42 52 Week High: $3.43 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -34.56% -36.27% 12 Week -1.83% -5.91% Year To Date -35.15% -43.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12278 SCRIPPS SUMMIT DRIVE - SAN DIEGO,CA 92131 USA ph: 858-875-1800 fax: - christina.tartaglia@sternir.com http://www.fatetherapeutics.com

• General Corporate Information    Officers Bahram Valamehr - President and Chief Executive Officer William H. Rastetter - Chairman John D. Mendlein - Vice Chairman Shefali Agarwal - Director Timothy P. Coughlin - Director Peer Information Fate Therapeutics, Inc. (CORR.) Fate Therapeutics, Inc. (RSPI) Fate Therapeutics, Inc. (CGXP) Fate Therapeutics, Inc. (BGEN) Fate Therapeutics, Inc. (GTBP) Fate Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31189P102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 115.33 Most Recent Split Date: (:1) Beta: 2.42 Market Capitalization: $123.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 22.28% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.47 Price/Cash Flow: - Price / Sales: 14.57 EPS Growth vs. Year Ago Period: 12.12% vs. Previous Quarter: 9.38% Sales Growth vs. Year Ago Period: -71.84% vs. Previous Quarter: 17.07% ROE 09/30/25 - - 06/30/25 - -50.95 03/31/25 - -47.17 ROA 09/30/25 - - 06/30/25 - -36.76 03/31/25 - -34.60 Current Ratio 09/30/25 - - 06/30/25 - 8.04 03/31/25 - 8.81 Quick Ratio 09/30/25 - - 06/30/25 - 8.04 03/31/25 - 8.81 Operating Margin 09/30/25 - - 06/30/25 - -1,851.06 03/31/25 - -1,208.41 Net Margin 09/30/25 - - 06/30/25 - -2,025.05 03/31/25 - -1,318.93 Pre-Tax Margin 09/30/25 - - 06/30/25 - -2,025.05 03/31/25 - -1,318.93 Book Value 09/30/25 - - 06/30/25 - 2.28 03/31/25 - 2.52 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©